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Abstract
Background: Vpx is a virion-associated protein encoded by SIVSM, a lentivirus endemic to the West African sooty
mangabey (Cercocebus atys). HIV-2 and SIVMAC, zoonoses resulting from SIVSM transmission to humans or Asian
rhesus macaques (Macaca mulatta), also encode Vpx. In myeloid cells, Vpx promotes reverse transcription and
transduction by these viruses. This activity correlates with Vpx binding to DCAF1 (VPRBP) and association with the
DDB1/RBX1/CUL4A E3 ubiquitin ligase complex. When delivered experimentally to myeloid cells using VSV G-
pseudotyped virus-like particles (VLPs), Vpx promotes reverse transcription of retroviruses that do not normally
encode Vpx.
Results: Here we show that Vpx has the extraordinary ability to completely rescue HIV-1 transduction of human
monocyte-derived dendritic cells (MDDCs) from the potent antiviral state established by prior treatment with
exogenous type 1 interferon (IFN). The magnitude of rescue was up to 1,000-fold, depending on the blood donor,
and was also observed after induction of endogenous IFN and IFN-stimulated genes (ISGs) by LPS, poly(I:C), or poly
(dA:dT). The effect was relatively specific in that Vpx-associated suppression of soluble IFN-b production, of mRNA
levels for ISGs, or of cell surface markers for MDDC differentiation, was not detected. Vpx did not rescue HIV-2 or
SIVMAC transduction from the antiviral state, even in the presence of SIVMAC or HIV-2 VLPs bearing additional Vpx,
or in the presence of HIV-1 VLPs bearing all accessory genes. In contrast to the effect of Vpx on transduction of
untreated MDDCs, HIV-1 rescue from the antiviral state was not dependent upon Vpx interaction with DCAF1 or on
the presence of DCAF1 within the MDDC target cells. Additionally, although Vpx increased the level of HIV-1
reverse transcripts in MDDCs to the same extent whether or not MDDCs were treated with IFN or LPS, Vpx rescued
a block specific to the antiviral state that occurred after HIV-1 cDNA penetrated the nucleus.
Conclusion: Vpx provides a tool for the characterization of a potent, new HIV-1 restriction activity, which acts in
the nucleus of type 1 IFN-treated dendritic cells.
Background
In addition to the gag, pol, and env genes common to all
retroviruses, lentiviruses including HIV-1 bear specia-
lized genes such as vpr that contribute to viral replica-
tion and pathogenesis [1]. Simian immunodeficiency
viruses isolated from West African sooty mangabeys
(SIVSM) possess vpr as well as a highly homologous
gene called vpx. The latter may have been generated by
vpr gene duplication [2] or by recombination with an
SIV that possessed a highly divergent vpx [3]. HIV-2
and SIVMAC, zoonoses derived from SIVSM,a l s op o s s e s s
both of these genes.
Neither vpr nor vpx is essential for virus replication in
tissue culture, but both contribute to virus replication
and disease progression in animal models [4,5]. The
effect of these genes in vivo is possibly linked to their
ability to enhance virus replication in dendritic cells and
macrophages in tissue culture [6-15]. Myeloid cells are
believed to be critical targets for lentiviruses in vivo,
partly because they are capable of productive infection,
but also because they facilitate virus transmission to
CD4
+ T-cells [16-18]. * Correspondence: jeremy.luban@unige.ch
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boxy-terminus of the Gag polyprotein, the Vpr and Vpx
proteins are incorporated into nascent virions as the
particles exit productively infected cells [19-22]. The
presence of these proteins within virions suggests that
they play a role in the early steps of lentivirus infection,
prior to de novo protein synthesis directed by transcripts
from the new provirus. Vpr and Vpx promote reverse
transcription soon after the virions enter the target cell
cytoplasm [10,13,14]. Other studies suggested that Vpr
and Vpx are required later in the retrovirus life cycle to
promote nuclear import of the preintegration complex
[23-26], though the significance of the latter findings
have been questioned [27,28].
Attempts to saturate a hypothetical HIV-1-specific
restriction factor in monocyte-derived dendritic cells
(MDDC) using HIV-1 VLPs have led to the fortuitous
discovery that SIVMAC VLPs increase HIV-1 reverse
transcription and infectivity in these cells, so long as the
VLPs possess Vpx [10,11,29]. Similar stimulation of
infectivity was observed with proteasome inhibitors, sug-
gesting that Vpx promotes the degradation of an anti-
viral factor; CUL5-dependent degradation of the
antiviral protein APOBEC3G by the lentiviral accessory
protein Vif offered compelling precedent for such a
model [30-32]. Indeed, heterokaryon experiments sug-
gested that myeloid cells possess a dominant-acting,
Vpx-sensitive inhibitor of lentiviral infection [12]. Via
direct binding to DCAF1 (also known as VPRBP), both
Vpr and Vpx associated with the DDB1/RBX1/CUL4A
E3 ubiquitin ligase complex [12,13,15,33-37]. Vpx
mutants that do not bind DCAF1 are unable to stimu-
late infectivity in myeloid cells [12,13,15].
Here, we report the results of experiments designed to
determine the effect of Vpx on HIV-1 transduction of
MDDCs in the face of the potent antiviral state pre-
established by treatment with exogenous type 1 inter-
feron (IFN) or with agonists of pattern recognition
receptor (PRRs) that stimulate endogenous type 1 IFN
production and the transcription of interferon stimu-
lated genes (ISGs).
Results
SIVMAC VLPs rescue HIV-1 infection from type I IFN
The Vpx proteins of SIVMAC and HIV-2 promote trans-
duction of myeloid cells by these viruses [6-15]. Though
HIV-1 does not possess a gene encoding Vpx, the infec-
tivity of HIV-1 in myeloid cells is also increased by SIV
virus-like particles (VLPs) bearing Vpx [10,11,29]. Inter-
est in potential links between retroviral restriction fac-
tors and innate immune signaling [38,39] directed us to
explore the effect of Vpx on HIV-1 transduction of
myeloid cells after an antiviral state had been established
by administration of exogenous type 1 IFN.
Human monocyte-derived dendritic cells (MDDC)
were generated by culture of CD14
+ peripheral blood
cells in GM-CSF and IL-4 for 4 days, as previously
described [39]. The status of differentiation and matura-
tion was confirmed by observing the typical morphology
and by assessing immunofluorescence for standard cell
surface markers, including CD1A, CD209 (DC-SIGN),
CD14, CD11C, HLA-DR, CD83, and CD86 (additional
file 1, Figure S1A and data not shown). When immature
MDDCs were challenged with three-part, HIV-1-GFP
reporter virus, pseudotyped with vesicular stomatitis
v i r u sg l y c o p r o t e i n( V S VG ) ,S I V MAC VLPs increased
transduction efficiency 3- to 10-fold (Figure 1A, upper
panels), depending upon the multiplicity of infection.
Challenge of MDDC with HIV-1-GFP 24 h after treat-
ment with exogenous IFN-a resulted in infection levels
at or below the detection limit (Figure 1A, lower left
panel). In the particular experiment shown in Figure 1,
the magnitude inhibition of HIV-1 transduction by IFN-
a was ≥ 600-fold. Addition of SIVMAC VLPs to the
MDDCs 24 h after IFN-a treatment rescued HIV-1
transduction to levels at least as high as those in the
absence of IFN-a (Figure 1A, lower right panel). Identi-
cal results were obtained when IFN-b was substituted
for IFN-a (Figure 1B).
SIVMAC VLPs rescue HIV-1 transduction of MDDC from
LPS, poly(I:C), or poly(dA:dT)
Lipopolysaccharide (LPS), the synthetic double-stranded
RNA poly(I:C), and the synthetic double-stranded DNA,
poly(dA:dT), each activate IFNB1 transcription and
establish a generalized antiviral state [39-42]. Treatment
of MDDC with LPS, poly(I:C), or poly(dA:dT) indeed
resulted in the production of soluble IFN-b (additional
file 1, Figure S1B), the synthesis of intracellular MX1
and APOBEC3A proteins (additional file 1, Figure S1C),
the transcriptional induction of IFNB1 and other inflam-
matory genes, including MX1, CCL2, CCL8, CXCL10,
IL6, ISG54 (IFIT2), PTGS2,a n dTNF (additional file 1,
Figure S1D), as well as the upregulation of MDDC cell
surface maturation markers, including CD86 and CD83
(additional file 1, Figure S1A).
Since LPS, poly(I:C), and poly(dA:dT) all elicited type
1 IFN in MDDCs, the ability of each to inhibit HIV-1
transduction was examined. MDDCs were treated for 24
h with either LPS, poly(I:C), or poly(dA:dT) and then
challenged with VSV G-pseudotyped HIV-1-GFP repor-
ter virus. Each of the treatments potently inhibited HIV-
1-GFP transduction (Figure 2A). When SIVMAC VLPs
were added to the culture 24 h after treatment with any
of the PRR agonists, HIV-1-GFP two-part vector trans-
duction was rescued completely (Figure 2A). Similar
results were observed when HIV-1 entry was mediated
by CCR5-tropic HIV-1 Env, indicating that the effect of
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(Figure 2B). The SIVMAC VLPs had no detectable effect
on IFN-b secretion, MX1 or APOBEC3A protein pro-
duction, cell-surface levels of MDDC maturation mar-
kers, or mRNA induction of IFNB1 and a panel of 8
ISGs (additional file 1, Figure S1). These findings indi-
cate that the effect of the SIVMAC VLPs was relatively
specific and that the VLPs did not globally reverse the
antiviral state associated with type 1 IFN.
Vpx is necessary and sufficient to protect HIV-1 from the
type I IFN response
Vpx is essential for the boost in HIV-1 transduction of
human MDDCs that is provided by SIVMAC VLPs
[10,11,29]. To determine if Vpx is also required for the
protective effect of VLPs in the context of the type 1
IFN-associated antiviral state, VLPs bearing Vpx were
compared with VLPs lacking Vpx. Either SIVMAC VLPs
or HIV-2 VLPs rescued a three-part HIV-1 vector from
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Figure 1 SIVMAC virus-like particles (VLPs) rescue HIV-1 transduction of human monocyte-derived dendritic cells (MDDCs) from
pretreatment with type I ifN. MDDCs were incubated for 24 h with 10 ng⁄mL IFN-a (A)o r1 0n g ⁄mL IFN-b (B). The cells were then treated for
3 h with media or VSV-G-pseudotyped SIVMAC-251 VLPs, followed by challenge with a VSV-G-pseudotyped HIV-1NL4-3 GFP reporter virus. The
percent GFP-positive cells was determined by flow cytometry 72 h after transduction. Error bars represent ± standard deviation (SD) (n = 3). In
each case, one representative example of at least three independent experiments is shown.
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Page 3 of 16type 1 IFN or LPS treatment in human MDDC, but only
when Vpx was present (Figure 3A). The same results
were obtained if vpx was provided in cis or in trans
with respect to the SIV structural proteins during
assembly of the VLPs (additional file 2, Figure S2A), if
Vpx was delivered by VLPs or whole SIV virus (addi-
tional file 2, Figure S2B), or if Vpx was encoded by
HIV-2ROD,S I V MAC251,S I V MAC239,o rS I V SMM-PBJ (data
not shown). Vpr encoded by SIVMAC, HIV-2, SIVAGM or
HIV-1 did not rescue HIV-1 from the antiviral state
and, if anything, decreased the efficiency of rescue by
Vpx (additional file 2, Figure S2B).
HIV-1 Gag p6 lacks the carboxy-terminal D-X-A-X-X-
L-L peptide found in SIVMAC and HIV-2 Gag that
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Figure 2 SIVMAC VLPs rescue HIV-1 infectivity from
pretreatment of MDDC with pattern recognition receptor (PRR)
agonists.( A) MDDCs were incubated for 24 h with recombinant
type I interferon (10 ng⁄mL IFN-a,1 0n g ⁄mL IFN-b), or PRR agonists
as indicated: 100 ng⁄mL LPS, 25 μg⁄mL poly(I:C) with no lipid carrier,
or 2 μg⁄mL poly(dA-dT). Then, cells were treated for 3 h with media
or VSV-G-pseudotyped SIVMAC-251 VLPs, followed by challenge with a
VSV G-pseudotyped HIV-1NL4-3 GFP reporter virus (A) or with a
CCR5-tropic, HIV-1NL4-3 GFP reporter virus (B). The percent GFP-
positive cells was determined by flow cytometry 72 h after addition
of the reporter virus. Error bars represent ± SD (n = 3). In each case,
one representative example of at least three independent
experiments is shown.
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Figure 3 Among VLP constituents, Vpx is necessary and
sufficient to rescue HIV-1 from type I IFN.( A) MDDCs were
treated with LPS for 24 hrs, then treated for 3 hrs with media or the
indicated VSV-G-pseudotyped HIV-2ROD or SIVMAC-251 VLPs, and
finally challenged with a VSV-G-pseudotyped HIV-1NL4-3 GFP reporter
virus. Infectivity was measured by flow cytometry. (B) As indicated,
293T cells were co-transfected with a codon optimized SIVMAC251
vpx expression plasmid and HIV-1 GFP reporter vectors bearing
either wild-type Gag or Gag with an engineered Vpx binding motif
(DPAVDLL). Proteins from the cell lysate and from virion
preparations were separated by SDS-PAGE and then immunoblotted
with anti-Vpx or anti-p24 antibodies. (C) MDDCs treated with IFN-b
for 24 h and were then challenged with VSV-G-pseudotyped HIV-1
GFP reporter vectors with wild-type HIV-1 Gag or HIV-1 Gag bearing
the engineered Vpx binding motif (DPAVDLL). Both HIV-1 reporter
vectors were produced in the presence of empty pcDNA3.1 plasmid
or pcDNA3.1 containing a codon-optimized SIVMAC-251 vpx cDNA.
Data are representative of one of at least three independent
experiments. Error bars represent ± SD (n = 3).
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[19-21,43,44]. Nonetheless, vpx expression in trans dur-
ing HIV-1 virion production has been reported to result
in some Vpx protein incorporation into HIV-1 virions
with concomitant increase in the efficiency of MDM
transduction by HIV-1 [12]. Vpx protein production
directed by a codon-optimized vpx expression plasmid
during HIV-1 virion production resulted in detectable
Vpx incorporation into HIV-1 virions (Figure 3B) and
partial rescue of HIV-1 three-part vector transduction in
MDDCs that had been treated 24 hrs previously with
IFN-b (Figure 3C). When the Vpx binding motif from
the carboxy terminus of SIVMAC Gag (DPAVDLL) was
engineered into HIV-1 Gag, Vpx packaging into HIV-1
virions was more efficient (Figure 3B) and rescue from
IFN-b by Vpx was 10-fold more effective than it was
with the parent construct (Figure 3C). These results
indicate that, of the SIVMAC VLP components, Vpx is
sufficient to rescue HIV-1 transduction from the type 1
IFN-associated antiviral state in MDDCs.
Vpx does not rescue HIV-2 or SIVMAC from the antiviral
state
As previously described [6,7,11,45], disruption of the vpx
open reading frame severely attenuated the transduction
of MDDCs by three-part SIVMAC vector (Figure 4A),
confirming the importance of vpx for MDDC-transduc-
tion in the absence of exogenous type 1 IFN or LPS. In
contrast, when an antiviral state was established with
exogenous IFN or LPS prior to virus challenge, vpx did
not rescue transduction by SIVMAC or HIV-2, even
when SIVMAC or HIV-2 VLPs provided additional Vpx
in trans (Figure 4 and additional file 3, Figure S3); in
parallel, the same SIVMAC VLPs rescued HIV-1 trans-
duction from the antiviral state in a vpx-dependent fash-
ion (Figure 4C). Additionally, HIV-1 VLPs bearing all
HIV-1 accessory genes were unable to rescue either
HIV-1 or SIVMAC from the antiviral state (Figure 4D
and 4E). These experiments demonstrate that Vpx has
the ability to rescue HIV-1, but not SIVMAC from the
antiviral state.
Rescue of HIV-1 from the antiviral state by Vpx is
independent of DCAF1
Vpx associates with the DDB1/RBX1/CUL4A E3 ubiqui-
tin ligase complex via interaction with DCAF1
[12,13,15]. SIVMAC replication in macrophages is com-
promised by disruption of Vpx association with DCAF1
using vpx mutations Q76A or F80A, or by knockdown
of DCAF1 or components of the DDB1/RBX1/CUL4A
complex [12,13,15,35]. To address the role of DCAF1
and the associated E3 ubiquitin ligase complex in rescue
of HIV-1 from the antiviral state in MDDCs, the Q76A
and F80A vpx mutations were introduced into a codon-
optimized SIVMAC vpx expression construct. Both
mutant proteins expressed as well as wild type Vpx (Fig-
ure 5A) and were efficiently incorporated into SIVMAC
VLPs (Figure 5B). As compared to the wild-type Vpx,
the efficiency of HIV-1 rescue from the antiviral state in
MDDCs by either mutant was reduced roughly 5-fold
(Figure 5C). Nonetheless, both mutants retained the
ability to rescue HIV-1 from the antiviral state 140-fold
(Figure 5C), indicating that interaction with DCAF1 is
not required for this activity.
The importance of DCAF1 for vpx-mediated rescue
from the antiviral state was examined directly by trans-
ducing MDDCs with lentiviral vectors engineered to
confer puromycin-resistance and to express RNA poly-
merase II-driven, microRNA-based short hairpin RNAs
targeting either DCAF1 or a control RNA [39,46].
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Figure 4 Vpx rescues HIV-1, but not SIVMAC or HIV-2, from the
type I IFN response in MDDC.( A) MDDCs were treated with the
indicated compounds for 24 h, and then challenged with VSV-G-
pseudotyped, vpx
+ or Δvpx SIVMAC GFP reporter virus. (B, C) MDDCs
were treated with the indicated compounds for 24 h, then treated
with either VSV-G-pseudotyped vpx
+ or Δvpx SIVMAC-251 VLPs, and
then challenged with either VSV-G-pseudotyped SIVMAC-239 (B)o r
HIV-1NL4-3 (C) GFP reporter viruses. (D, E) MDDCs were treated with
LPS, then treated with either media or VSV-G pseudotyped HIV-1NL4-
3 or SIVMAC-239 VLPs (containing all accessory genes) for 3 h, and
then challenged with either VSV-G-pseudotyped SIVMAC-239 (D)o r
HIV-1NL4-3 (E) GFP reporter viruses. Data are representative of one of
at least three independent experiments. Error bars represent ± SD
(n = 3).
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Page 5 of 16t h ep r e s e n c eo fS I V MAC VLPs to increase the effective
titer of the knockdown vectors. Cells were placed in
GM-CSF and IL-4, and pools of puromycin-resistant
cells were generated with each knockdown vector, as
previously described [39,46].
Lysate from MDDCs that had been transduced with
knockdown vector targeting DCAF1 was examined by
Western blot. In contrast to the strong signal observed
with the control knockdown cells, DCAF1 protein was
undetectable in the DCAF1-knockdown cells (Figure
6A), even after cells had been treated with exogenous
IFN-b. The ability of the cells to respond to IFN-b was
confirmed by showing the induction of Mx1 protein
(Figure 6A). Despite this highly efficient DCAF1 knock-
down, little change was observed in the ability of Vpx to
rescue HIV-1 transduction from the antiviral state
established by IFN-b or by LPS (Figure 6B and 6C).
Parallel experiments in MDDCs from the same donor
showed that transduction with SIVMAC was efficiently
blocked by IFN-b or by LPS (Figure 6C), demonstrating
that the antiviral state had been well-established in
these cells.
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dispensable for Vpx-mediated rescue of HIV-1 from the
antiviral state.( A) 293T cells were transfected with FLAG-tagged
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containing the indicated alanine-substitution mutations that disrupt
associated with DCAF1. Immune complexes were isolated from
clarified, 0.5% CHAPSO detergent lysates using anti-FLAG antibody
conjugated to Protein G magnetic beads. Panels show immunoblots
(IB) of the immunoprecipiated (IP) proteins (top panels) and
immunoblots of the inputs (bottom panels). (B) Immunoblots of
wild-type Vpx and the indicated mutants incorporated into SIVMAC-
251 VLPs (top panels) and expression in the 293T producer cells
(bottom panels). (C) MDDCs were treated with LPS, then treated
with SIVMAC-251 VLPs containing wild-type Vpx or the indicated
mutants, and challenged with an HIV-1NL4-3 GFP reporter virus. Data
represent one of at least three independent experiments. Error bars
represent ± SD (n = 3).
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Figure 6 DCAF1 (VPRBP) knockdown does not prevent Vpx
rescue of HIV-1 from the antiviral state in MDDCs. MDDCs were
transduced with lentiviral knockdown vectors targeting either
DCAF1, or a control RNA, in the presence of SIV VLPs. DCAF1 KD
and control KD cells were then treated with IFN-b for 24 hrs, and
lysates were probed in immunoblots with antibodies against the
indicated proteins (A), or cells were challenged with a VSV-G-
pseudotyped HIV-1NL4-3 GFP reporter virus (B). (C) DCAF1 KD and
control KD MDDCs were treated with LPS for 24 h, and challenged
with either VSV-G-pseudotyped HIV-1NL4-3 or SIVMAC-239 GFP reporter
viruses. Data represent one of at least three independent
experiments. Error bars represent ± SD (n = 3).
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Page 6 of 16The IFN-specific, vpx-sensitive block to HIV-1 is in the
MDDC nucleus
Vpx is required for the synthesis of SIVMAC or HIV-2
cDNA after infection of MDDCs or MDMs [10,13,14].
VLPs bearing Vpx similarly increase the levels of nas-
cent HIV-1 cDNA after infection of these cell types
[10]. In the absence of exogenous IFN, Vpx
+ VLPs
indeed increased the levels of full-length linear HIV-1
cDNA (Figure 7A). The increase in the levels of 2-LTR
circles (Figure 7B) and Alu-PCR products (Figure 7C)
were of comparable magnitude. Heat-inactivated virus
and virions generated in the absence of Env were used
as controls to demonstrate that the PCR products were
a reflection of de novo cDNA synthesis in the target
cells and were not the result of contaminating plasmid
DNA carried over from the transfection used to gener-
ate the viruses. These experiments indicate that, in the
absence of exogenous IFN, the main effect of Vpx is to
increase the efficiency of HIV-1 reverse transcription.
When MDDCs were treated with IFN-a prior to chal-
lenge with HIV-1, the magnitude rescue of full-length
viral cDNA and 2-LTR circles by Vpx was identical to
the magnitude rescue by Vpx in the absence of
exogenous IFN (Figure 7D). In contrast, the magnitude
rescue of proviral DNA by Vpx was at least 12-fold
greater when MDDCs had been treated with exogenous
IFN than with untreated MDDCs (Figure 7C and 7D).
The magnitude of this rescue possibly underestimates
the real difference, since the Alu-PCR signal was below
the limit of detection when DNA from IFN-treated cells
was used as template, even after 50 cycles of amplifica-
tion. These data indicate that the IFN-specific effect of
Vpx in MDDCs occurs after the preintegration complex
is transported to the MDDC nucleus.
Conclusions
The experiments presented here demonstrate that SIV-
MAC/HIV-2 Vpx rescues HIV-1 from the antiviral state
established by exogenous type I IFN or LPS in MDDCs.
This phenotype is truly extraordinary in that Vpx
o f f e r e dc o m p l e t er e s c u eo fH I V - 1 ,a f t e rt h ea n t i v i r a l
state had been fully established, and the magnitude of
the rescue approached 1000-fold. Surprisingly, the pre-
sence of Vpx in SIVMAC or HIV-2 did not protect these
viruses from IFN-b or LPS treatment, even when target
cell MDDCs were treated with VLPs bearing additional
Vpx prior to challenge with reporter virus. Although
Vpx is not normally an HIV-1 accessory protein, it pro-
vides a powerful tool that will aid attempts to identify
new HIV-1 restriction factors that are elicited by IFN in
dendritic cells.
Elucidation of the mechanism by which Vpx rescues
HIV-1 from the antiviral state would be aided enor-
mously by an experimental system that exploits a cell
line. Among cell lines tested, the most pronounced phe-
notype was observed with the acute monocytic leukemia
cell line THP-1 [47], which had been treated with phor-
bol esters to promote differentiation into macrophages,
as we reported previously to study Vpx and innate
immune signaling [11,39]. The magnitude inhibition of
HIV-1 transduction by LPS or IFN-b in THP-1 macro-
phages [11,39] was 10-fold less than that seen in
MDDC. Of greater concern, though, rescue of HIV-1
from the antiviral state by Vpx
+ VLPs in these cells was
only 2 to 10-fold (data not shown). Ongoing mechanis-
tic studies concerning the Vpx phenotype reported here,
then, will likely not be possible with a cell line.
HIV-1 transduction of monocyte-derived macrophages
(MDMs) was also greatly stimulated by Vpx; although,
in the absence of exogenous IFN, HIV-1 transduction
efficiency was lower in these cells than in MDDCs (data
not shown). A necessary consequence is that a smaller
proportion of the Vpx effect in MDMs was specific to
the antiviral state. In other words, the magnitude rescue
of HIV-1 by Vpx following establishment of the antiviral
state with exogenous IFN was most evident in MDDCs.
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Figure 7 SIVMAC Vpx rescues HIV-1 from the antiviral state in
MDDC prior to establishment of the provirus. MDDCs were
treated with IFN-a for 24 h, and then treated with SIVMAC VLPs or
media for 3 h, and finally challenged with a VSV-G-pseudotyped
HIV-1NL4-3 GFP reporter virus. Total DNA was extracted from 5 × 10
6
MDDCs and qPCR was performed for HIV-1 full-length linear reverse
transcription products (A), 2-LTR circles (B), and provirus (C). (D)
Data from A, B, C, represented as (fold-rescue of HIV-1 by Vpx from
IFN-a treatment) divided by (fold-rescue of HIV-1 by Vpx in the
absence of exogenous IFN). Data represent one of at least three
independent experiments. Error bars represent ± SEM (n = 4).
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Page 7 of 16might express an HIV-1-specific, Vpx-sensitive, anti-
viral effector at higher levels than do MDMs. Alterna-
tively, constitutive expression levels of this putative fac-
tor might be higher in MDMs.
Viruses often encode factors that prevent establish-
ment of the antiviral state. For example, hepatitis C
virus, poliovirus, and rhinovirus proteases degrade
MDA-5, RIG-I, IPS-1, and TRIF [48-53]. In the experi-
mental system reported here, Vpx was administered
after the antiviral state was fully established. Therefore,
Vpx does not act by blocking induction of the antiviral
state. This is consistent with the observation that vpx
had no significant effect on the transcriptional induc-
tion of luciferase reporters for critical innate immune
factors, including IFN-b,N F - B, or AP-1 (additional
file 4, Figure S4).
Additionally, Vpx appears not to launch a global shut-
down of the antiviral state. It caused no change in levels
of MDDC cell surface markers for maturation, in IFN-b
secretion and steady-state protein levels for MX1 and
APOBEC3A, or in steady-state levels of mRNAs pro-
duced by 8 ISGs (additional file 1, Figure S1). More
importantly, Vpx did not rescue SIVMAC or HIV-2, indi-
cating that the antiviral state was very much intact fol-
lowing exposure to Vpx. More likely, Vpx inactivates an
HIV-1-specific antiviral effector that is induced by IFN.
This inactivation might involve degradation, the same
way that Vif promotes the degradation of APOBEC3G
[30-32] or Vpu promotes the degradation of
TETHERIN [54-56]. Alternatively, Vpx might sequester
the putative factor, blocking it without assistance from
ubiquitination machinery, as may also be the case with
Vif and Vpu [57,58].
Though it has been known for over 20 years that type
1 IFN and LPS block HIV-1 infection of myeloid cells
[40], the effector proteins responsible for the block to
HIV-1 transduction of IFN-treated MDDCs is not
known. Several ISG-encoded proteins inhibit HIV-1,
APOBEC3G [59] and Tetherin [60,61] being prominent
among them. These host restriction factors pose obsta-
cles to infection of sufficient importance that HIV-1
maintains two of its nine genes - vif and vpu,r e s p e c -
tively - to counteract them. Neither Vif nor Vpu is
required for the phenotype reported here since Vpx res-
cued minimal HIV-1 vectors lacking all viral accessory
proteins as efficiently as it rescued full HIV-1 virus.
Additionally, the best-characterized phenotypes of Vif
and Vpu require their presence during virion assembly
and the experiments reported here likely involve effects
of Vpx that are restricted to the target cell.
TRIM5, another restriction factor encoded by an ISG,
is required for establishment of an antiviral state by LPS
in MDDCs [39]. Nonetheless, endogenous human
TRIM5 is unlikely to be a direct antiviral effector in the
experiments reported here since inhibition of HIV-1
transduction by exogenous type 1 IFN is not reversed
by TRIM5 knockdown [39]. Other TRIM proteins are
encoded by ISGs [62], and some of these exhibit anti-
viral activity [63]. TRIM22, for example, blocks HIV-1
LTR-directed transcription [64], but the putative anti-
viral effector in IFN-treated MDDCs acts before integra-
tion, as documented by Alu-PCR (Figure 7).
Additionally, TRIM22 does not block transcription from
the heterologous promoter (SFFVp) used in the trans-
duction vectors here [64].
In the course of examining ISG expression levels in
MDDCs it was observed that, in response to exogenous
type 1 IFN or LPS, APOBEC3A mRNA levels increased
nearly 10,000-fold and the protein levels also increased
to an impressive extent (additional file 1, Figure S1C).
APOBEC3A is a nuclear protein [65,66] and therefore a
reasonable candidate for the Vpx-sensitive, IFN-stimu-
lated, anti-HIV-1 effector protein. Specific association of
APOBEC3A with Vpx was not detected in co-transfec-
tion experiments in 293T cells, and no effect on inhibi-
tion of HIV-1 was observed when APOBEC3A
knockdown was attempted with lentiviral vectors or
with transfected double-stranded RNA oligonucleotides
(data not shown). These findings are in contrast to
reports that Vpx associates with APOBEC3A and that a
vpx mutant that does not bind to APOBEC3A failed to
stimulate HIV-1 infection of monocytes [67]. APO-
BEC3A knockdown was also reported to render mono-
cytes more permissive for HIV-1 [68]. These
discrepancies with the results reported here might be
due to cell type differences, i.e, monocytes versus
MDDCs, or other differences in methodology.
Vpx was recently shown to bind to SAMHD1 and
promote the degradation of this myeloid cell protein
[69,70]. While SAMHD1 is clearly a Vpx-sensitive inhi-
bitor of HIV-1 replication in myeloid cells, it does not
appear to be the IFN-stimulated HIV-1 inhibitor
described here. SAMHD1 knockdown in THP-1 cells
results in more than 10-fold increase in HIV-1 replica-
tion [70]; in contrast to the enormous effect of Vpx in
IFN-treated MDDCs, HIV-1 infection of IFN-treated
THP-1 cells increases only two to three-fold in response
to Vpx.
Both Vpr and Vpx bind DCAF1 (VPRBP) and associ-
ate with the DDB1/RBX1/CUL4A E3 ubiquitin ligase
complex [12,13,15,33-37,71,72]. Vpr might, therefore, be
expected to interfere with Vpx binding to DCAF1 and
the E3 complex. However, the presence of HIV-1 Vpr
or SIVMAC Vpr did not significantly alter the ability of
SIVMAC Vpx to protect HIV-1 from the antiviral state,
underlying the unique ability of Vpx to protect HIV-1.
The unexpected finding that Vpx mutant proteins that
do not bind to DCAF1 (Figure 5A and references
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exogenous IFN indicates that the DCAF1/DDB1/RBX1/
CUL4A E3 ubiquitin ligase complex is dispensable for
the phenotype reported here. Consistent with this result
was the demonstration that Vpx rescued HIV-1 in the
presence of an effective DCAF1 knockdown (Figure 6).
While the DCAF1/DDB1/RBX1/CUL4A E3 ubiquitin
ligase complex, and Vpx, is clearly required for SIVMAC
to infect human macrophages in the absence of exogen-
ous type 1 IFN [12], Vpx interaction with DCAF1 was
a l s on o tr e q u i r e df o rH I V - 1t r a n s d u c t i o no fT H P - 1
macrophages [11]. These results indicate that, if Vpx
rescues HIV-1 from the antiviral state by promoting the
degradation of an antiviral effector, it does so by recruit-
ing a yet-to-be-identified E3 ubiquitin ligase complex.
As previously reported [10,13,14], Vpx had a large
effect on HIV-1 reverse transcription in transduced
MDDCs (Figure 7). An additional effect of Vpx was
observed, though, that was specific to the cells that
had been treated with exogenous type 1 IFN: Vpx
overcame a block to HIV-1 transduction that occurred
after the virus had entered the target cell nucleus (Fig-
ure 7). Thus, it may be that Vpx protects HIV-1 from
more than one antiviral factor. The first factor is con-
stitutively expressed in myeloid cells and blocks
reverse transcription. The second factor is induced by
IFN and acts in the nucleus to block transduction.
HIV-1 CA and IN, two proteins essential at this stage
of the HIV-1 replication cycle [28,73,74], would be
likely targets of this antiviral factor. To date, attempts
to demonstrate the importance of these proteins by
transferring Vpx-responsiveness using chimeric viruses
have not been successful due to the poor infectivity of
these constructs in highly permissive cell lines, let
alone in MDDCs.
Why does Vpx protect HIV-1, and not SIVMAC or
HIV-2, from the antiviral state in MDDCs? A number
of scenarios are possible. It might be that there is an
IFN-inducible, HIV-1-specific inhibitor, which is sup-
pressed by Vpx. This factor might be induced by the
recently reported HIV-1-specific, cryptic sensor in
MDDCs [75]. In this case, one would need to invoke an
additional, IFN-induced, SIVMAC-specific factor, which
i sn o ts u p p r e s s e db yV p x .A l t ernatively, there might be
a single IFN-induced inhibitor of both viruses, from
which Vpx offers protection to HIV-1 but not to SIV-
MAC. Whichever scenario is correct, identification of
antiviral factors such as these has the potential to guide
development of new drugs for inhibiting HIV-1 replica-
tion in the clinical context. Additionally, given the criti-
cal role of dendritic cells at the interface between the
innate and acquired immune systems [76,77], identifica-
tion of such factors may aid attempts to understand
how the innate immune system detects HIV-1, and
assist efforts to stimulate acquired immune responses to
HIV-1 [39,78].
Methods
Ethics statement
Buffy-coats obtained from anonymous blood donors
were provided by the Blood Transfusion Center of the
Hematology Service of the University Hospital of Gen-
eva by agreement with the Service, after approval of our
project by Ethics Committee of the University Hospital
of Geneva (Ref# 0704).
Chemicals and drugs
The following compounds were used at the given final
concentrations: Ultrapure LPS from E. coli K12 (100 ng/
mL), poly(I:C) (25 μg/mL, or 2 μg/mL when complexed
with Lipofectamine 2000 (Invitrogen)), and poly(dA:dT)
(2 μg/mL) were obtained from Invivogen. Recombinant,
human IFN-b (10 ng/mL) and recombinant, human
IFN-a2a (10 ng/mL) were obtained from PBL Interfer-
onSource. All other chemicals and drugs were obtained
from Sigma-Aldrich, unless otherwise noted.
Cell lines and primary cell cultures
HEK-293 and 293T cells were obtained from American
Type Culture Collection (ATCC) and were grown in
Dulbecco’s modified Eagle medium (D-MEM) (high glu-
cose) (Invitrogen) supplemented with 10% fetal bovine
serum (FBS) (Hyclone), 1 × MEM Non-Essential Amino
Acids (NEAA) Solution (Invitrogen), and 1 × Gluta-
MAX-I (Invitrogen). 293T cells were periodically grown
in cell culture medium containing 500 μg/mL Geneticin
(Invitrogen) to maintain expression of the SV40 large T
antigen.
THP-1 cells were obtained from ATCC and main-
tained in RPMI-1640 (Invitrogen) supplemented with
10% FBS, 20 mmol/L HEPES (Invitrogen), 1 × MEM
NEAA, and 1 × GlutaMAX-I. In order to differentiate
THP-1 monocytes into macrophage-like cells, THP-1
cells were counted, centrifuged at 200 × g for 10 min,
and resuspended at a concentration of 1 × 10
6 cells/mL
in fresh cell culture medium containing 100 ng/mL
phorbol 12-myristate 13-acetate (PMA). Cells were pla-
ted into each well of a sterile tissue culture plate (2 mL
culture/well of a 6-well plate or 200 μL culture/well of a
96-well flat-bottom plate) and allowed to differentiate
for 24 h, at which point the PMA-containing medium
was removed and fresh cell culture medium (without
PMA) was added. The cells were rested for an additional
48 h before use.
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from buffy coats prepared from healthy, anon-
ymous donors using Ficoll-Paque Plus (GE Healthcare)
following the protocol supplied by Miltenyi Biotec.
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+ cells (monocytes) were enriched from PBMCs by
positive selection using CD14 MicroBeads (Miltenyi Bio-
tec) with purity routinely greater than 95%, as deter-
mined by flow cytometry after staining with PE anti-
human CD14 (BD Biosciences). Enriched CD14
+ cells
were counted, centrifuged at 200 × g for 10 min, and
resuspended in RPMI-1640 supplemented with 10%
FBS, 20 mmol/L HEPES, 1 × MEM NEAA, and 1 × Glu-
taMAX-I, at a concentration of 1 × 10
6 cells/mL. In
order to generate monocyte-derived macrophages
(MDM), recombinant, human GM-CSF (R&D Systems)
was added to the cell suspension to a final concentration
of 50 ng/mL, and in order to generate monocyte-derived
dendritic cells (MDDC), recombinant, human IL-4
(R&D Systems) was added to a final concentration of 25
ng/mL along with 50 ng/mL GM-CSF. CD14
+ cells were
allowed to either differentiate into MDDCs in the pre-
sence of GM-CSF and IL-4 for 4 d, or into MDMs in
the presence of GM-CSF alone for 10 d, before use. The
following antibodies were used for flow cytometry: APC
anti-CD86 (BU63) was from EXBIO; FITC anti-CD1a
(HI149), PE anti-CD209 (DC-SIGN) (DCN46), and
APC-anti-CD83 (HB15e) were from BD Biosciences. Iso-
type controls were from Miltenyi Biotec.
All primary cells and cultured cell lines were main-
tained in cell culture media without penicillin or strep-
tomycin, and were cultured at 37°C in a humidified
incubator containing 5% carbon dioxide.
Plasmids, Vectors, and Viruses
SIVMAC-251 vpx,H I V - 2 ROD vpx,S I V SMM-PBj vpx,a n d
SIVAGM-TAN vpr were codon-optimized for expression
in human cells using services provided by Sloning Bio-
Technology GmbH (Puchheim, Germany). See addi-
tional file 5, Table S1 for the codon-optimized nucleic
acid sequences. The codon optimized cDNAs were
cloned into pcDNA3.1(-) (Invitrogen) by PCR using the
primer pairs listed in additional file 6, Table S2. Alanine
substitution mutations were introduced into the codon-
optimized SIVMAC-251 vpx cDNA by overlapping PCR,
using the primer sets detailed in additional file 6, Table
S2. APOBEC3A, APOBEC3A:Myc:6 × His, APOBEC3G,
and APOBEC3G:Myc:6 × His expression constructs
were provided by Dr. Klaus Strebel (National Institute
of Allergy and Infectious Diseases, NIH). FLAG:HA:
AU1:DCAF1 and FLAG:HA:AU1:DDB1 expression con-
structs were provided by Dr. Jacek Skowronski (Case
Western Reserve University).
pFSGW, an HIV-1-based transfer vector with EGFP
expression under the control of the spleen focus-form-
ing virus (SFFV) long terminal repeat (LTR), as well as
gag-pol and VSV G expression plasmids, are described
elsewhere [39]. pSIV3+, a SIVMAC-251 gag-pol expression
plasmid [79], and pSIV3+Δvpx, generated by digest with
BstB1 and religation after blunting ends with DNA Poly-
merase I, Large (Klenow) Fragment (New England Bio-
Labs), introducing a premature stop codon at amino
acid 25 of vpx, were provided by Dr. Andrea Cimarelli
(École Normale Supérieure de Lyon). pNL4-3 NefNA7:
GFP (CCR5-tropic), which bears the V3 loop of the
CCR5-tropic 92TH014-2 HIV-1 strain and where
NefNA7 is fused to EGFP [80,81]. pNL4-3.GFP.E- [82]
and pNL4-3.Luc.E- [83] are pNL4-3 with an env
- inacti-
vating mutation and EGFP or luciferase, respectively,
cloned in place of nef. The HIV-2 and HIV-2Δvpx
packaging plasmids, as well as the HIV-2 GFP transfer
vector, are described elsewhere [10]. p8.9NDSB is a
minimal HIV-1 packaging plasmid [84]. The SIVMAC
Vpx binding motif (DPAVDLL) was generated and
introduced into HIV-1 Gag p6 by overlapping PCR and
cloned into the BglII and BclI sites of p8.9NDSB using
the following primers: p6 BglII 5’:5 ’-TAGGGAA-
GATCTGGCCTTCCCACAA-3’,p 6V p xi n s3 ’:5 ’-TAG-
CAGATCCACAGCTGGGTCTTCTGGTGGGGCTG
TTGGCTCTGG-3’,p 6V p xi n s5 ’:5 ’-GACCCAG
CTGTGGATCTGCTAGAGAGCTTCAGGTTTGGGGA
AGA-3’,p 6B c l I3 ’:5 ’-ATGAGTATCTGATCATACT
GTCTTACTT-3’.S I V MAC-239 env
- GFP is described
elsewhere [85]. psSIV-GAE is pSIV-GAE [86], a SIV-
MAC-251 transfer vector expressing GFP, where the cyto-
megalovirus (CMV) promoter driving EGFP expression
was replaced with the SFFV LTR, amplified by PCR
from pFSGW.
Production of viruses, vectors, and virus-like particles
(VLPs)
Viruses, minimal vectors, and VLPs were produced by
transfection of 293T cells using Lipofectamine 2000 (Invi-
trogen), according to the manufacturer’s instructions. For
three-part vector systems, the following DNA ratio was
used: 4 parts transfer vector: 3 parts packaging plasmid: 1
part envelope. For two-part virus systems a 7:1 ratio was
used (7 parts env
- virus: 1 part envelope). For VLPs, a 7:1
ratio was used (7 parts gag-pol expression plasmid: 1 part
envelope). 16 h after transfection the transfection medium
was replaced with fresh target-cell medium. 48 h after
transfection the supernatant was collected, centrifuged at
200 × g for 5 min, filtered through a sterile 0.45 μms y r -
inge filter (Millipore), and stored in 1 mL aliquots at -80°
C. When comparing viruses, vectors, or VLPs, samples
were normalized by single-cycle infectivity assays on HEK-
293 cells and/or the reverse transcriptase (RT) activity pre-
sent in the viral supernatant by qRT-PCR [87].
RNAi in primary human monocyte-derived dendritic cells
and macrophages
To generate stable microRNA-based shRNA knock-
downs in primary human MDDC or MDM, human
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+ cells, freshly isolated from PBMC as described
above, were treated with SIVMAC-251 VLPs for 3 h, and
then transduced with either a control or experimental
pAPM microRNA-based shRNA vectors [39]. The CD14
+ cells were then allowed to differentiate into MDDC or
MDM as described above. After differentiation, the
MDDC or MDM were selected with 10 μg/mL puromy-
cin dihydrochloride for 3 d and assayed for knockdown
by SDS-PAGE/western blot and/or qRT-PCR analysis.
Using this technique we routinely observed greater than
90% transduced MDDC or MDM. shRNA target
sequences used: Luciferase:5 ’-TACAAACGCTCT-
CATCGACAAG-3’, APOBEC3A 5’-TTGGCTTCA-
TATCTAGACTAAC-3’, DCAF1 (VPRBP): 5’-
AGCACTTCAGATTATCATCAAT-3’.
For transient siRNA in MDM, 5 × 10
5 cells were pla-
ted in each well of a 6-well plate. 600 pmol of ON-
TARGETplus siRNA Smart pools (Thermo Scientific
Dharmacon) targeting DCAF1, APOBEC3A,o rc o n t r o l
siRNA were complexed with 5 μL Lipofectamine 2000
(Invitrogen), following the manufacturer’si n s t r u c t i o n s ,
and added to 2 mL of cell culture media. The transfec-
tion medium was removed after 6 h and replaced with
fresh cell culture medium. Knockdown was assessed by
SDS-PAGE/western blot and/or qRT-PCR analysis 48-72
h after transfection. For transient siRNA in MDDC, 8 ×
10
5 were plated in each well of a 12-well plate in 600
μL culture medium. 100 nM of FlexiTube GeneSolu-
tions pooled siRNAs (Qiagen) targeting DCAF1, APO-
BEC3A, or control siRNA were complexed with 6 μLo f
HiPerFect Transfection Reagent (Qiagen), following the
manufacturer’s instructions, and added to the MDDC
culture. A second round of transfection was performed
24 h later. Knockdown was assessed by SDS-PAGE/wes-
tern blot and/or qRT-PCR analysis 24-48 h after the
second transfection.
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from 2 × 10
6 cells using the
RNeasy Plus Mini Kit (Qiagen), following the manufac-
turer’s instructions. First-strand cDNA was generated
using the SuperScript III First-Strand Synthesis System
(Invitrogen) using 2 μgt o t a lR N Aa n dr a n d o mh e x a m -
ers, according to the manufacturer’s protocol. The qPCR
reaction was performed in triplicate in a 20 μLv o l u m e
using 1 × TaqMan Gene Expression Master Mix
(Applied Biosystems), 1 μLo fu n d i l u t e dc D N A ,a n d1
μL of the specified TaqMan Gene Expression Assay
(Applied Biosystems) on either the 7900HT Fast Real-
Time PCR System (Applied Biosystems) or the CFX96
Real Time System/C1000 Thermal Cycler (Bio-Rad)
using the following program: 95°C for 10 min and 45
cycles of 95°C for 15 s and 60°C for 1 min. The
following TaqMan Gene Expression Assays were used:
APOBEC3A (Hs00377444_m1), APOBEC3G (Hs00
222415_m1), CCL2 (Hs00234140_m1), CCL8 (Hs00
271615_m1), CUL4A (Hs00757716_m1), CXCL10 (Hs00
171042_m1), DDB1 (Hs00172410_m1), IFIT1 (Hs00
356631_g1), IFIT2 (Hs00533665_m1), IFNB1 (Hs01
077958_s1), IL6 (Hs00985639_m1), MX1 (Hs00
182073_m1), PTGS2 (Hs00153133_m1), TNF (Hs00
174128_m1), TRIM5 (Hs01552558_m1), and VPRBP
(Hs00206762_m1). OAZ1 (Hs00427923_m1) was used as
an endogenous control. Data were analyzed using the
SDS software v2.2.2 (Applied Biosystems) or the CFX
Manager software v1.6 (Bio-Rad), which calculate rela-
tive mRNA expression levels using the standard com-
parative Ct method (2
-ΔΔCt) with error bars representing
± the standard error of the mean.
Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE)/western blot analysis
2×1 0
6 cells were lysed in 200 μL 1 × Laemmli sample
buffer (62.5 mmol/L Tris, pH 6.8, 2% SDS, 10% glycerol,
357.5 mmol/L 2-mercaptoethanol (2-ME), 0.0025% bro-
mophenol blue (Bio-Rad)), supplemented with 1 × Halt
Protease and Phosphatase Inhibitor Cocktail, EDTA-free
(Thermo Fisher Scientific) and 5 mmol/L EDTA, pH
8.0. Whole-cell lysates were heated at 100°C for 5 min,
centrifuged at 14, 000 × g for 2 min, and 50 μLw e r e
loaded onto a 10% ProSieve 50 gel (Lonza) for SDS-
PAGE. Relative protein concentration was normalized
after staining the gel with SimplyBlue SafeStain (Invitro-
gen). After SDS-PAGE, proteins were transferred onto
an Immun-Blot polyvinylidene fluoride (PVDF) mem-
brane (Bio-Rad) for 16 h at 30 V (constant voltage) at 4°
C. After the protein transfer, the membrane was washed
3 × 5 min with deionized water and blocked 1 h at 4°C
with 5% non-fat dry milk dissolved in TBST (Tris-buf-
fered saline (50 mmol/L Tris, pH 7.4, 150 mmol/L
sodium chloride (NaCl)) with 0.1% Polysorbate 20
(Tween 20)). The membrane was then washed 3 × 5
min with TBST. The primary antibody was diluted to 1
μg/mL in 5% non-fat dry milk dissolved in TBST and
added to the membrane and incubated 16 h at 4°C with
gentle rocking. After the 16 h incubation with the pri-
mary antibody the membrane was washed 3 × 5 min
with TBST. The secondary antibody was diluted
1:10,000 in 5% non-fat dry milk dissolved in TBST and
added to the washed membrane and incubated at room
temperature for 1 h with gentle rocking. The membrane
was washed 3 × 10 min and developed using either the
ECL or ECL Plus Western Blotting Detection Reagents
(GE Healthcare Life Sciences) and exposed to Hyperfilm
ECL film (GE Healthcare Life Sciences).
The following antibodies were used in this study: rab-
b i ta n t i - V P R B P( D C A F 1 )a n dr a b b i ta n t i - M X 1w e r e
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Page 11 of 16from Proteintech Group; rabbit anti-APOBEC3A/APO-
BEC3G serum was a generous gift from Dr. Klaus Stre-
bel (National Institute of Allergy and Infectious
Diseases, NIH); mouse anti-FLAG (M2), rabbit anti-
FLAG, mouse anti c-Myc (9E10), rabbit anti-c-Myc,
mouse anti-HA (HA-7), rabbit anti-HA, and mouse
anti-b-Actin (AC-74) were from Sigma-Aldrich. The fol-
lowing reagents were obtained through the AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH: monoclonal antibody to HIV-1 p24
(SIVMAC p27) (AG3.0) [88] from Dr. Jonathan Allan and
HIV-2 Vpx Monoclonal Antibody (6D2.6) [89] from Dr.
John C. Kappes. Secondary antibodies used: HRP-linked
donkey anti-rabbit IgG and HRP-linked sheep anti-
mouse IgG were from GE Healthcare Life Sciences.
Immunoprecipitation (IP)
Sub-confluent 293T cells grown on T-75 tissue culture
flasks were transfected with 16 μgt o t a lp l a s m i dD N A
using TransIT-LT1 Transfection Reagent (Mirus Bio),
following the manufacturer’s protocol. 40 h post-trans-
fection, cells were washed with 30 mL ice-cold phos-
phate buffered saline (PBS) (Invitrogen) and lysed with 1
mL ice-cold lysis buffer (50 mmol/L Tris, pH 7.4, 150
mmol/L NaCl, 0.5% CHAPSO (Affymetrix)) supplemen-
ted with 1 × Halt Protease and Phosphatase Inhibitor
Cocktail, EDTA-free (Thermo Fisher Scientific). Crude
cell lysates were scraped off the surface of the flask,
transferred to pre-chilled 2 mL microcentrifuge tubes,
and rotated at 4°C for 20 min. The crude cell lysates
were then centrifuged at 14,000 × g for 10 min and 900
μL of the clarified lysate was transferred to pre-chilled
microcentrifuge tubes, and the remaining 100 μLo ft h e
clarified lysate was diluted equally in 2 × Laemmli sam-
ple buffer, incubated at 100°C for 5 min, and stored at
-80°C. 2 μg antibody was conjugated to 50 μL of Protein
G Dynabeads (Invitrogen) following the manufacturer’s
protocol. The beads were washed 3 times with 1 mL
ice-cold lysis buffer, resuspended in 100 μL lysis buffer,
and added to the clarified cell lysates. After 2 h rotating
at 4°C, the Protein G magnetic bead immune complexes
were washed 4 times with 1 mL ice-cold lysis buffer,
resuspended in 100 μL of 1 × Laemmli sample buffer,
incubated at 100°C for 5 min, and stored at -80°C until
ready for SDS-PAGE.
Vpx incorporation assay
Using TransIT-LT1 Transfection Reagent (Mirus Bio),
sub-confluent 293T cells grown on T-75 flasks were
transfected with the following plasmids: for SIVMAC-251
Vpx incorporation in HIV-1, 14 μg p8.9NDSB (contain-
ing HIV-1 Gag WT) or p8.9NDSB-DPAVDLL (contain-
ing HIV-1 Gag with the SIVMAC Vpx binding motif
inserted into p6) along with 2 μg empty pcDNA3.1(-) or
pcDNA3.1(-) expressing codon-optimized SIVMAC-251
vpx WT; for SIVMAC-251 Vpx incorporation into SIV-
MAC-251,1 4μgp S I V 3 + Δvpx and 2 μg empty pcDNA3.1
(-) or pcDNA3.1(-) expressing codon-optimized SIV-
MAC-251 vpx WT or the indicated mutants. 40 h after
transfection, the medium was collected, clarified by cen-
trifugation for 10 min at 500 × g, and filtered through a
sterile 0.45 μm syringe filter (Millipore). The superna-
tant was then overlaid on 8 mL of TNE buffer (50
mmol/L Tris pH 7.5, 140 mmol/L NaCl, 5 mmol/L
EDTA, pH 8.0) containing 25% (w/v) sucrose in a 30
mL Beckman Coulter ultracentrifuge tube, and subjected
to 26,000 rpm for 90 min. The supernatant was then
removed and the pellet was dissolved in 1 × Laemmli
sample buffer, heated at 100°C for 5 min, and stored at
-80°C until SDS-PAGE.
Luciferase assays
HEK-293 cells were plated on white, opaque 96-well Cul-
turPlate-96 microplates (PerkinElmer) at a concentration
of 2 × 10
4 cells per 100 μL tissue culture medium per
well, 24 h prior to transfection. Cells were transfected
with Lipofectamine 2000, using 0.5 μL Lipofectamine
2000 per well, with 1 ng of the Renilla luciferase internal
control reporter plasmid pRL-TK (Promega), 5 ng firefly
luciferase experimental reporter plasmid, and 15 to 50 ng
of pcDNA3.1(-) containing the experimental cDNA or
empty pcDNA3.1(-) as a control, following the manufac-
turer’s instructions. Each experimental condition was
performed in sextuplicate. 48 h after transfection, the
plate was assayed using the Dual-Glo Luciferase Assay
System (Promega) and read using a Veritas Microplate
Luminometer (Turner Biosystems). Firefly luciferase
readings were normalized to Renilla luciferase readings
in each well, and the data are represented as fold-change
compared to empty pcDNA3.1(-) (± the standard devia-
tion). The following firefly luciferase plasmids were used:
the IFNB1- l u cc o n s t r u c tw a sag i f tf r o mD r .J ü r g
Tschopp (University of Lausanne); the Prl promoter AP-
1-luc construct was from Dr. Ruslan Medzhitov (Yale
School of Medicine), and the NF-B-luc construct was
from Dr. Jurgen Brojatsch (Albert Einstein College of
Medicine). The MAVS, MYD88, and TAB3 expression
constructs are described elsewhere [39].
For single-cycle infectivity assays using the env
- luci-
ferase reporter viruses described above, HEK-293 cells
or THP-1 macrophages were plated on white, opaque
96-well CulturPlate-96 microplates (PerkinElmer) at 1 ×
10
5 cells per well in 100 μLt i s s u ec u l t u r em e d i u m .
After 24 h, the cells were challenged with serial dilutions
of luciferase reporter viruses. 72 h after transduction the
plate was assayed using the Bright-Glo Luciferase Assay
System (Promega) and read using a Veritas Microplate
Luminometer (Turner Biosystems).
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IFN-b secretion was quantified using the reporter cell
line HL116, which carries the luciferase gene under the
control of the IFN-inducible 6-16 promoter [90] (a kind
gift from Dr. Olivier Schwartz, (Institut Pasteur)).
HL116 cells, grown in DMEM supplemented with 10%
FBS and hypoxanthine-aminopterin-thymidine (HAT)
media supplement, were plated at 2 × 10
4 cells per well
of a 96-well plate, 16 h prior to the assay. The HL116
cells were then incubated for 7 h with the culture med-
ium from MDDC challenged with SIVMAC-251 VLPs or a
control for 3 h, and then treated with LPS. A titration
of recombinant, human IFN-b (PBL InterferonSource)
was used as a standard. Cells were then lysed with Luci-
ferase Cell Culture Lysis 5 × Reagent (Promega) and
luciferase activity was measured using the Luciferase
Assay Reagent (Promega), following the manufacturer’s
instructions.
qPCR for viral cDNA
qPCR for HIV-1 full-length linear cDNA and 2-LTR cir-
cles was performed as described previously [91,92], with
the following modifications. The qPCR reaction was per-
formed in quadruplicate in a 20 μLv o l u m eu s i n g1×
TaqMan Universal PCR Master Mix (Applied Biosys-
tems), 500 ng of total cellular DNA (isolated from 5 ×
10
6 MDDC using the DNeasy Blood & Tissue Kit (Qia-
gen)), and 300 nmol/L forward primer, 300 nmol/L
reverse primer, and 100 nmol/L probe. Using the 7900
HT Fast Real-Time PCR System (Applied Biosystems),
the following program was performed: 50°C for 2 min,
95°C for 10 min, then 40 cycles of 95°C for 15 s and 60°
C for 1 min. The following primer and probe sets were
used: Late RT: J1 5’-ACAAGCTAGTACCAGTTGAGC-
CAGATAAG-3’,J 25 ’- GCCGTGCGCGCTTCAG-
CAAGC-3’, Late RT probe (LRT-P) 5’-( F A M ) -
CAGTGGCGCCCGAACAGGGA-(TAMRA)-3’;2 - L T R
circles: 2-LTR forward (MH535): 5’-AACTAGG-
GAACCCACTGCTTAAG-3’, 2-LTR reverse (MH536)
5’-TCCACAGATCAAGGATATCTTGTC-3’,2 - L T R
probe (MH603) 5’-(FAM)-ACACTACTTGAAGCACT-
CAAGGCAAGCTTT-(TAMRA) -3’.
Nested Alu-LTR qPCR for HIV-1 provirus was per-
formed as described previously [91,93] with the follow-
ing modifications. Total DNA was prepared from 5 ×
10
6 cells using the DNeasy Blood and Tissue Kit (Qia-
gen). 500 ng total DNA was diluted in a 50 μL reaction
with 1 × AccuPrime PCR Buffer II (Invitrogen), 0.2 μL
AccuPrime High Fidelity Taq polymerase (Invitrogen),
and 400 nmol/L of each primer (Alu forward (MH535)
5’-AACTAGGGAACCCACTGCTTAAG-3’ and Alu
reverse (SB704) 5’-TGCTGGGATTACAGGCGTGAG-
3’). After 2 min denaturing at 94°C, 25 cycles of 94°C
for 15 s, 55°C for 30 s, and 68°C for 3 min were
performed, followed by a 10 min extension at 68°C. The
second round of amplification using a nested primer/
probe set was performed in quadruplicate in a 20 μL
volume using 1 × TaqMan Universal PCR Master Mix
(Applied Biosystems), 2 μLo ft h ef i r s tr o u n dP C Ra s
template, 300 nmol/L of each forward and reverse pri-
mer, and 100 nmol/L probe on the 7900HT Fast Real-
Time PCR System (Applied Biosystems) using the stan-
dard mode program with the following changes: 50°C
for 2 min, 95°C for 10 min, and 50 cycles of 95°C for 15
s and 60°C for 90 s. The following primer/probe combi-
nations were used: Alu II forward 5’-GGTAACTAGA-
GATCCCTCAGACCCT-3’, Alu II reverse 5’-
GCGTGAGCCACCGC-3’, Alu II probe 5’-(FAM)-
TTAGTCAGTGTGGAAAATCTCTAGCAGGCCG-
(TAMRA)-3’.
Mitochondrial DNA was used as an internal control
with the following primer/probe set: Mito forward
(MH533) 5’-ACCCACTCCCTCTTAGCCAATATT-3’,
Mito reverse (MH534) 5’-GTAGGGCTAGGCCCACCG-
3’,M i t op r o b e5 ’-(TET)-CTAGTCTTTGCCGCCTGC-
GAAGCA-(TAMRA)-3’ [91].
Additional material
Additional file 1: Figure S1. SIVMAC vpx
+ VLPs do not disrupt innate
immune responses in MDDC.( A) MDDCs were treated with vpx
+ or
Δvpx SIVMAC-251 VLPs or media as a control for 3 h, and then treated with
the indicated compounds for 24 h. Upregulated surface expression of
CD86 on MDDC was then determined by flow cytometry. (B) MDDCs
were treated with vpx
+ or Δvpx SIVMAC-251 VLPs for 3 h, and then treated
with LPS for 24 h. The MDDC media was then collected and added to
HL116 cells, which carry the luciferase gene under the control of the IFN-
inducible 6-16 promoter, for 7 h. The HL116 cells were then subjected to
a luciferase assay to quantify endogenous IFN-b protein levels in the
MDDC media, as compared to a standard curve of known, recombinant
IFN-b levels. (C) MDDCs were treated with vpx
+ or Δvpx SIVMAC-251 VLPs
for 3 h, and then treated with the indicated compounds for 24 h. Whole-
cell lysates were prepared from MDDC and subjected to SDS-PAGE/
western blot analysis. Membranes were probed with the indicated
antibodies. (D) MDDCs were treated with vpx
+ or Δvpx SIVMAC-251 VLPs for
3 h, and then treated with LPS for 2 h. Total RNA was extracted from
MDDC and subjected to qRT-PCR analysis with the indicated Taqman-
based gene expression assays. Data represent one of at least three
independent experiments. Error bars represent ± SD (n = 3).
Additional file 2: Figure S2. Vpx is necessary to rescue HIV-1 from
the type I IFN response in MDDC. (A) MDDCs were treated with the
indicated compounds for 24 h and then treated for 3 h with media or
VSV-G-pseudotyped SIVMAC-251 VLPs where vpx is either supplied in cis or
in trans, or where vpx is deleted entirely. 72 h after challenge with a VSV-
G-pseudotyped HIV-1NL4-3 GFP reporter virus, the MDDC were assayed by
flow cytometry for GFP expression. (B) MDDCs were treated with the
indicated compounds for 24 h and then treated for 3 h with media, or
with the indicated VSV-G-pseudotyped SIVMAC-239 luciferase reporter
viruses, and then challenged with a VSV-G-pseudotyped HIV-1NL4-3 GFP
reporter virus. MDDC were analyzed by flow cytometry 72 h after
transduction. Data represent one of at least three independent
experiments. Error bars represent ± SD (n = 3).
Additional file 3: Figure S3. Vpx does not protect SIVMAC or HIV-2
from the type I interferon response in MDDC. MDDCs were treated
with LPS for 24 h and then treated with media, or the indicated vpx
+ or
Δvpx SIVMAC-251 or HIV-2ROD VLPs for 3 h. The MDDC were then
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vector. MDDCs were analyzed by flow cytometry 72 h after transduction.
Data represent one of at least three independent experiments. Error bars
represent ± SD (n = 3).
Additional file 4: Figure S4. Vpx does not disrupt innate immune
signaling. HEK-293 cells were transfected with codon-optimzed SIVMAC-
251 vpx or empty pcDNA3.1 plasmid as a control, along with a luciferase
reporter plasmid for IFNΒ1 (A), NF-B( B), or AP-1 (C), and an expression
plasmid for MAVS (A), MyD88 (B), or TAB3 (C). Cells were harvested for
luciferase assay 48 h post-transfection. Data are normalized to a Renilla
luciferase internal control and are representative of one of at least three
independent experiments. Error bars represent ± SD (n = 6).
Additional file 5: Table S1. Codon-optimized nucleic acid sequences.
Additional file 6: Table S2. Oligonucleotides used for cloning in this
study.
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